Comments
Commented by Armin Schulz on April 4th, 2025 | 07:10 CEST
Bayer's cancer drugs, Defence Therapeutics' cancer vaccine, Novo Nordisk's fat burner – Back on the road to success through specialization
The new trade tariffs threaten to destabilize the global supply chains of the pharmaceutical industry, increase the prices of generic drugs, and slow innovation cycles. The only winners in this environment will be those who focus on unique innovations to ensure resilience and growth. Bayer is trying to make itself fit for the future with an efficiency program, new pharmaceutical products, and digital agriculture platforms. Defence Therapeutics excels with precision-medicine cancer vaccines based on patented technology, opening up new markets. Novo Nordisk, in turn, is shaping a multibillion-dollar market with GLP-1 therapies for obesity and diabetes based on closed production cycles. These three approaches show how specialization and adaptability open new paths in turbulent times.
Read
Commented by Juliane Zielonka on April 4th, 2025 | 07:00 CEST
MiMedia, Porsche, and Xiaomi: A focus on innovation, dividends, and growth
The companies MiMedia, Porsche SE, and Xiaomi impressively demonstrate how innovation and strategic expansion can drive growth in different industries. The New York-based technology company MiMedia is revolutionizing the market for cloud storage solutions by integrating its platform directly into smartphones. With over 35 million preinstalled devices in the next two years, MiMedia expects high revenue potential and is targeting a rapidly growing target group in Latin America. Porsche SE reported a bumpy fiscal year and plans to pay a dividend of EUR 1.91 per preference share. Xiaomi is expanding its expertise in the field of electric vehicles. The technology group is financing the expansion of its EV division, which already generated billions in revenue last year, with a share placement of USD 5.5 billion. We provide an overview of investment opportunities.
Read
Commented by Juliane Zielonka on April 3rd, 2025 | 08:15 CEST
Leisure time in focus: TUI, naoo AG and PUMA share under the microscope
Leisure time and vacations shape the quality of life – and offer opportunities for investors. Whether travel, shared experiences, or sporty fashion, the desire for recreation, experiences, and an active lifestyle provides companies such as TUI, naoo, and PUMA inexhaustible customer groups. As a travel provider, TUI stands for the classic vacation dream and scores with package tours in the upper segment, as well as a billion-dollar cruise deal that has boosted its share price. The Swiss company naoo AG combines everything that makes up social media today in its leisure app: events, games and, most recently, influencer marketing. No wonder the share price is on a growth trajectory. PUMA has discovered the circular economy and is now combining sporty fashion with sustainability. Which strategy is most convincing to investors?
Read
Commented by Armin Schulz on April 3rd, 2025 | 07:30 CEST
Tungsten shortage as a goldmine: Why Almonty Industries is becoming a key player for NATO countries
As early as the beginning of December 2024, there were initial indications that China would impose certain restrictions on its tungsten exports. After the Chinese government further tightened export control on tungsten and molybdenum in early February 2025, Western industries have been increasingly seeking reliable alternatives. While Beijing leverages its dominance in critical metals as a geopolitical lever, companies like Almonty Industries are benefiting by building independent supply chains. With strategic partnerships, a relocation of its headquarters to the US, and the revival of one of South Korea's largest tungsten mines, the Company is positioning itself as a key player in a market characterized by scarcity and increasing demand.
Read
Commented by Fabian Lorenz on April 3rd, 2025 | 07:20 CEST
Stock set for 100% rally! Evotec, thyssenkrupp, Vidac Pharma - A golden April ahead?
Can shareholders look forward to a 100% price gain soon? If analysts have their way, this could be imminent for Evotec. However, shareholders must first mark an important date in April, as the medium-term share price performance is likely to be decided then. For Vidac Pharma, analysts see even greater upside potential, making the current price weakness an interesting entry opportunity. After all, the biotech company is making operational progress. One of the surprises of the current week is thyssenkrupp. The Company is benefiting from billions being spent in defense and infrastructure. Now, it could also benefit from Trump's tariff policies. Analysts recommend buying.
Read
Commented by Juliane Zielonka on April 3rd, 2025 | 07:10 CEST
Novo Nordisk, BioNxt Solutions, Bayer: Three ways to health and returns
The pharmaceutical industry is booming, and three companies are set to be in the spotlight in 2025: Novo Nordisk, BioNxt Solutions, and Bayer. A common goal unites all three: To improve the health of millions of patients through innovative approaches. Investors have the opportunity to participate in their success. While their strategies differ, their focus on research, new therapies, and growth makes them exciting for investors. Novo Nordisk stands out with its obesity drug Wegovy. It reduces the risk of heart disease by 57% – a potential game changer, as obesity is a major contributor to severe cardiovascular diseases. BioNxt Solutions is leveraging fresh capital and future technologies. The Company is developing novel drug delivery systems, including sublingual films, transdermal patches, and oral tablets for autoimmune diseases like multiple sclerosis. With CAD 2.5 million from a private placement, it is ready for the next step. Bayer is pushing ahead with its broad pharmaceutical offensive. In 2025, the Leverkusen-based company will launch drugs for the treatment of cardiovascular diseases, oncology, and women's health – areas with high medical demand and market potential.
Read
Commented by André Will-Laudien on April 2nd, 2025 | 09:05 CEST
Tesla is out; SMRs are in! Green hydrogen in focus at nucera, Nel ASA, Plug Power, First Hydrogen, and Oklo
Even if Donald Trump denies climate change, the international community still has hydrogen and alternative energies on the agenda. Within the new US administration, nuclear projects have been under discussion for several months, alongside an emphasis on fossil fuels. Small modular reactors (SMRs) are being discussed in this context. They can be planned and put into operation in a much shorter time and are highly flexible in their applications. In the US, Oklo is moving forward in this area, and the Canadian company First Hydrogen is also in the starting blocks to roll out its innovative solutions. This means that green hydrogen remains in focus. Which stocks are coming to the fore?
Read
Commented by Armin Schulz on April 2nd, 2025 | 07:20 CEST
dynaCERT: Government-backed, certified, profitable – Driving your returns green
The Ontario government is leading by example – and dynaCERT could be one of the beneficiaries. The Canadian cleantech company, known for its revolutionary HydraGEN™ technology, is receiving government support in a market that is hungry for solutions for more efficient mobility and measurable CO₂ reductions. In an era when climate goals and economic considerations can no longer be at odds, dynaCERT is positioning itself as a bridge between ecology and economy. A new player is emerging here in the billion-dollar market for emission certificates.
Read
Commented by Armin Schulz on April 2nd, 2025 | 07:10 CEST
Steyr Motors, Power Metallic Mines, BYD – From unique selling point to market leader
In the context of geopolitical tariffs and green transformation, drive technology, raw material extraction, and e-mobility are merging into key sectors. While US automotive tariffs are setting new rules from 2025, three players are driving systemic solutions: Steyr Motors, a pioneer in high-performance hybrid engines; Power Metallic Mines, which is setting ESG standards with carbon-neutral nickel; and BYD, which is dominating e-mobility through innovation. Their strategies – technological sovereignty, vertical integration, and resource-efficient ecosystems – demonstrate how the apparent contradictions between decarbonization and industrial reality can be overcome. Three companies, one mission: to shape the value chain of tomorrow.
Read
Commented by Armin Schulz on April 2nd, 2025 | 07:00 CEST
RENK – The armaments hype is waning. First Phosphate and Volkswagen are taking advantage of the upswing in electromobility!
The demand for armaments stocks is waning. Despite record orders for tank transmissions from the RENK Group and global security investments, the defense boom is flattening out - partly because these stocks have become fundamentally expensive. At the same time, electromobility is gathering pace: The EU predicts a 38% increase in the number of electric vehicles registered in 2025, driven by Germany's planned tax breaks and subsidies for hybrids. This surge requires raw materials to produce lithium iron phosphate batteries, which is where First Phosphate comes into play. Meanwhile, Volkswagen is currently exploring the production of military vehicles, but is also pushing into the market with new electric vehicles and charging systems. Investments for the future should flow into green technologies, not tank production.
Read